ArticleVirulence2025
Tilmicosin inhibits the infections of currently prevalent porcine reproductive and respiratory syndrome viruses via the downregulation of CD163 expression.
Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cross-Species Reactivity and Differential Anti-PRRSV Activities of CD163 SRCR4/SRCR5 Monoclonal Antibodies.Veterinary sciences · 2026Article
- The updated one-step multiplex RT-qPCR method for PRRSV classical strains, highly pathogenic strains and NADC30-like strains.Frontiers in microbiology · 2026Article
- Numb-Associated Kinases-Mediated AP2M1 Activation Facilitates Porcine Reproductive and Respiratory Syndrome Virus Entry.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) has a disastrous impact on the global swine industry. Even though PRRS commercial vaccines can provide homologous protection, broadly effective anti-PRRSV strategies are still in urgent need. Tilmicosin is a semi-synthetic macrolide antibiotic that was noticed to have anti-PRRSV capacity in the field. However, the antiviral activities of tilmicosin against currently prevalent PRRSV isolates have not been systematically evaluated. More importantly, the anti-PRRSV mechanisms of tilmicosin are not clarified. In this study,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.